Mangrove Partners Cel Sci Corp Put Options Transaction History

Mangrove Partners

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2021 Nov 15, 2021	SELL	$7.64 - $12.49 $6.88 Million - $11.2 Million	-900,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$8.68 - $27.49 $5.64 Million - $17.9 Million	-649,900 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $7.81 Million - $24.7 Million	900,000 New	900,000 $7.81 Million
Q1 2021 May 17, 2021	BUY	$12.0 - $27.64 $7.8 Million - $18 Million	649,900 New	649,900 $9.89 Million
Q2 2020 Aug 14, 2020	SELL	$9.75 - $17.6 $276,900 - $499,840	-28,400 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$7.54 - $17.05 $214,136 - $484,220	28,400 New	28,400 $328,000

6.15M

16.6K

148K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.